Extent to which weight loss contributes to improving metabolic dysfunction-associated and metabolic and alcohol related/associated steatotic liver disease: a study on Japanese participants undergoing health checkups

被引:3
|
作者
Fukuda, Tatsuya [1 ,2 ,3 ]
Okamoto, Takahiro [1 ]
Fukaishi, Takahiro [4 ]
Kawakami, Akio [5 ]
Tanaka, Makoto [4 ]
Yamada, Tetsuya [3 ]
Monzen, Koshiro [5 ]
机构
[1] Mirraza Shinjuku Tsurukame Clin, Tokyo, Japan
[2] Tokyo Metropolitan Okubo Hosp, Dept Endocrinol & Metab, Tokyo, Japan
[3] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Mol Endocrinol & Metab, Tokyo, Japan
[4] Koganei Tsurukame Clin, Tokyo, Japan
[5] Shinjuku Tsurukame Clin, Tokyo, Japan
来源
FRONTIERS IN ENDOCRINOLOGY | 2024年 / 15卷
关键词
metabolic dysfunction-associated steatotic liver disease (MASLD); nonalcoholic fatty liver disease (NAFLD); metabolic and alcohol related/associated liver disease (MetALD); alcohol consumption; weight loss; INDEX; ASIA;
D O I
10.3389/fendo.2024.1392280
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The incidence of steatotic liver disease has increased in recent years. Thus, steatotic liver disease is a major public health issue in Japan. This study investigated the association between weight reduction and the remission of metabolic dysfunction-associated steatotic liver disease (MASLD)/Metabolic and alcohol related/associated liver disease (MetALD) in Japanese individuals undergoing health checkups.Methods This retrospective observational study included 8,707 Japanese patients with MASLD/MetALD who underwent health checkups from May 2015 to March 2023. The participants were monitored for its remission at their subsequent visit. MASLD was diagnosed on abdominal ultrasonography and based on the presence of at least one of five metabolic abnormalities. The impact of body mass index (BMI) reduction on MASLD/MetALD remission was assessed via logistic regression analysis and using receiver operating characteristic curves.Results Logistic regression analysis revealed that weight loss was significantly associated with MASLD/MetALD remission. Other factors including exercise habits and reduced alcohol consumption were significant predictors of MASLD/MetALD remission in the overall cohort and in male patients. The optimal BMI reduction cutoff values for MASLD/MetALD remission were 0.9 kg/m2 and 4.0% decrease in the overall cohort, 0.85 kg/m2 and 3.9% decrease in males, and 1.2 kg/m2 and 4.5% decrease in females. In participants with a BMI of 23 kg/m2, the cutoff values were 0.75 kg/m2 and 2.7% BMI reduction.Discussion Weight reduction plays an important role in both MASLD and MetALD remission among Japanese individuals. That is, targeting specific BMI reduction is effective. This underscores the importance of targeted weight management strategies in preventing and managing MASLD/MetALD in the Japanese population.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] Relationship between anthropometric measures and the risk of incident Metabolic dysfunction-associated steatotic liver disease: a longitudinal study
    Ichikawa, Takahiro
    Hashimoto, Yoshitaka
    Okamura, Takuro
    Obora, Akihiro
    Kojima, Takao
    Okada, Hiroshi
    Hamaguchi, Masahide
    Fukui, Michiaki
    BMC GASTROENTEROLOGY, 2025, 25 (01)
  • [42] Weight Loss After Sleeve Gastrectomy According to Metabolic Dysfunction-Associated Steatotic Liver Disease Stage in Patients with Obesity: A Liver Biopsy-Based Prospective Study
    Martinez-Montoro, Jose Ignacio
    Arranz-Salas, Isabel
    Gutierrez-Repiso, Carolina
    Sanchez-Garcia, Ana
    Ocana-Wilhelmi, Luis
    Pinazo-Bandera, Jose M.
    Fernandez-Garcia, Diego
    Munoz-Garach, Araceli
    Morales-Garcia, Dieter
    Garcia-Cortes, Miren
    Garcia-Fuentes, Eduardo
    Tinahones, Francisco J.
    Garrido-Sanchez, Lourdes
    NUTRIENTS, 2024, 16 (22)
  • [43] Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
    Jeong, Seogsong
    Oh, Yun Hwan
    Ahn, Joseph C.
    Choi, Seulggie
    Park, Sun Jae
    Kim, Hye Jun
    Lee, Gyeongsil
    Son, Joung Sik
    Jang, Heejoon
    Lee, Dong Hyeon
    Sha, Meng
    Chen, Lei
    Kim, Won
    Park, Sang Min
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (03) : 487 - 499
  • [44] Clinical care guidance in patients with diabetes and metabolic dysfunction-associated steatotic liver disease: A joint consensus
    Huang, Jee-Fu
    Chang, Tien-Jyun
    Yeh, Ming-Lun
    Shen, Feng-Chih
    Tai, Chi-Ming
    Chen, Jung-Fu
    Huang, Yi-Hsiang
    Hsu, Chih-Yao
    Cheng, Pin-Nan
    Lin, Ching-Ling
    Hung, Chao-Hung
    Chen, Ching-Chu
    Lee, Mei-Hsuan
    Lee, Chun-Chuan
    Lin, Chih-Wen
    Liu, Sung-Chen
    Yang, Hwai-, I
    Chien, Rong-Nan
    Kuo, Chin-Sung
    Peng, Cheng-Yuan
    Chang, Ming-Ling
    Huang, Chung-Feng
    Yang, Yi-Sun
    Yang, Hung-Chih
    Lin, Han-Chieh
    Ou, Horng-Yih
    Liu, Chun-Jen
    Tseng, Chin-Hsiao
    Kao, Jia-Horng
    Chuang, Wan-Long
    Huang, Chien-Ning
    Chen, Pei-Jer
    Wang, Chih-Yuan
    Yu, Ming-Lung
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (11)
  • [45] Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus- faced modernity
    Kim, Gi-Ae
    Moon, Joon Ho
    Kim, Won
    CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 (04) : 831 - 843
  • [46] Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges
    Xie, Chencheng
    Alkhouri, Naim
    Elfeki, Mohamed A.
    WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (05) : 731 - 750
  • [47] Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population
    Chew, Nicholas W. S.
    Pan, Xin Hui
    Chong, Bryan
    Chandramouli, Chanchal
    Muthiah, Mark
    Lam, Carolyn S. P.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2024, 211
  • [48] Efficacy of fish oil supplementation on metabolic dysfunction-associated steatotic liver disease: a meta-analysis
    Zhou, Like
    Sun, Dongmei
    Bai, Houqiao
    FRONTIERS IN NUTRITION, 2025, 12
  • [49] Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period
    Mori, Kazuma
    Tanaka, Marenao
    Sato, Tatsuya
    Akiyama, Yukinori
    Endo, Keisuke
    Ogawa, Toshifumi
    Suzuki, Toru
    Aida, Hiroki
    Kawaharata, Wataru
    Nakata, Kei
    Hosaka, Itaru
    Umetsu, Araya
    Hanawa, Nagisa
    Furuhashi, Masato
    HEPATOLOGY RESEARCH, 2025, 55 (01) : 34 - 45
  • [50] Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study
    Cho, So Hyun
    Kim, Seohyun
    Oh, Rosa
    Kim, Ji Yoon
    Lee, You-Bin
    Jin, Sang-Man
    Hur, Kyu Yeon
    Kim, Gyuri
    Kim, Jae Hyeon
    HEPATOLOGY INTERNATIONAL, 2024, 18 (04) : 1168 - 1177